Département des sciences de l'activité physique, Université du Québec à Trois-Rivières (UQTR), Trois-Rivières, Quebec, Canada.
Groupe de recherche sur les affections neuromusculosquelettiques, Trois-Rivières, Québec, Canada.
Brain Inj. 2022 Jul 3;36(8):977-984. doi: 10.1080/02699052.2022.2109738. Epub 2022 Aug 10.
Neurocognitive assessment tools such as the Neurotracker and ImPACT have been proposed to optimize sports-related mild traumatic brain injury (mTBI) management. Baseline testing is recommended with such assessments to individualize monitoring of athletes' remission. While the ideal timeframe between baseline updates has been studied for the ImPACT, these data are missing for the Neurotracker.
The current study aimed to compare the test-retest reliability of the ImPACT and Neurotracker for two consecutive seasons in university athletes participating in sports at risk for mTBI.
At the start of two consecutive seasons, 30 athletes with no recent history of mTBI completed a baseline assessment including the Neurotracker and the ImPACT. The test-retest reliability of the results was analyzed by considering intra-class correlation (ICC), Becker's standardized mean difference (d) and Bland-Altman' plot of each outcome.
The Neurotracker and the Visual Motor Speed composite score of the ImPAC were the only outcomes with significative ICCs and acceptable between the two seasons. Neurotracker was the only outcome with a significative bias (+0.179).
Our research suggests that the Neurotracker has an acceptable level of test-retest reliability after one year in comparison to the ImPACT.
神经认知评估工具,如 Neurotracker 和 ImPACT,已被提议用于优化与运动相关的轻度创伤性脑损伤(mTBI)管理。建议对这些评估进行基线测试,以个性化监测运动员的缓解情况。虽然已经研究了 ImPACT 进行基线更新的理想时间框架,但对于 Neurotracker,这些数据尚不清楚。
本研究旨在比较在有发生 mTBI 风险的运动中参与的大学生运动员连续两个赛季中,ImPACT 和 Neurotracker 的测试-重测可靠性。
在连续两个赛季开始时,30 名无近期 mTBI 病史的运动员完成了基线评估,包括 Neurotracker 和 ImPACT。通过考虑组内相关系数(ICC)、Becker 标准化平均差异(d)和每个结果的 Bland-Altman 图来分析结果的测试-重测可靠性。
Neurotracker 和 ImPACT 的视觉运动速度综合评分是仅有的两个具有显著 ICC 和可接受的两个赛季之间差异的结果。Neurotracker 是唯一具有显著偏差(+0.179)的结果。
与 ImPACT 相比,我们的研究表明,Neurotracker 在经过一年后具有可接受的测试-重测可靠性水平。